Skip to main content
SpringerLink
Log in
Book cover

Management des MAMMAKARZINOMS pp 295–323Cite as

Systemische Therapie des metastasierten Mammakarzinoms

  • Chapter

  • 73 Accesses

Part of the book series: Onkologie ((ONKAKTUELL))

Zusammenfassung

Bis heute gilt das Dogma, dass das metastasierte Mammakarzinom nicht mehr kurativ behandelt werden kann. Die mittlere Überlebenszeit nach Feststellung der Metastasierung beträgt im Median 2 Jahre. Sie ist etwas länger bei Patientinnen, deren Tumor hormonrezeptorpositiv ist oder die eine klinisch komplette Remission unter konventioneller Chemotherapie erzielen. Beim Nachweis viszeraler Metastasen ist die Prognose deutlich ungünstiger als bei einer ausschließlichen Knochen- oder Weichteilmetastasierung, was in den Therapieempfehlungen des Possinger-Score Berücksichtigung findet. Ob das Dogma der Inkurabilität, z. B. durch den Einsatz der Hochdosischemotherapie für ein zu definierendes Kollektiv, aufgehoben werden kann, ist unwahrscheinlich.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Acuna LR, Langhi M, Pérez J et al. (1999) Vinorelbine and Pac-litaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17: 74–81

    CAS  Google Scholar 

  • Australian New Zealand Breast Cancer Trials Group (1986) A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 4:186–193

    Google Scholar 

  • Barni S, Frontin L, Villa S et al. (1993) Vinorelbine (VNR) in pretreated advanced breast cancer (ABC). Eur J Cancer 29 A (suppl 6): 418 (abstr)

    Google Scholar 

  • Batist G, Ramakrishnan G, Sekhar Rao C et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cnacer. J Clin Oncol 19:1444–1454

    PubMed  CAS  Google Scholar 

  • Berlie J, Meeus L, Meyer C et al. (1990) Protracted continuous infusion of 5-fluorouracil among breast cancer patients. Proc Am Soc Clin Oncol 9:40 (abstr)

    Google Scholar 

  • Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13: 2483–2489

    PubMed  CAS  Google Scholar 

  • Biganzoli L, Cufer T, Bruning P, Coleman R et al. (2000) Doxorubicin (A)/Taxol (T) versus Doxorubicin/Cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): A phase III study. Proc Am Soc Clin Oncol 19:282 (abstract)

    Google Scholar 

  • Blum JL, Jones SE, Buzdar AU et al. (1999) Multicenter phase II study of Capecitabine in Paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493

    PubMed  CAS  Google Scholar 

  • Bonneterre J, Thürlimann B, Robertson JFR et al. (2000) Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. Journal of Clinical Oncology 18 (22): 3748–3757

    PubMed  CAS  Google Scholar 

  • Buchanan RB, Blaney RW, Durant KR et al. (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326–1330(1986)

    PubMed  CAS  Google Scholar 

  • Burstein HJ, Manola J, Younger J et al. (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212–1219

    PubMed  CAS  Google Scholar 

  • Buzdar A, Jonat W, Howell A et al, Arimidex Study Group (1996) Anastrozole, a potent and selective aromatase inhibitor, versus Megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 14/7:2000–2011

    PubMed  CAS  Google Scholar 

  • Buzdar A, Jonat W, Howell A, Yin H, Lee D, Arimidex International Study Group (1997a) Significant improved survival with Arimidex (Anastrozole) versus Megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc Am Soc Clin Oncol 16:156a (Abstr 545) (33rd Ann Meeting Am Soc Clin Oncol ASCO, Denver 1997)

    Google Scholar 

  • Buzdar AU, Jones SE, Vogel CL, Walter J, Plourde P, Webster A, Arimidex Study Group (1997b) A phase III trial comparing Anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with Megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 79/4: 730–739

    Article  PubMed  CAS  Google Scholar 

  • Carmichael J, Walling J (1996) Phase II activity of Gemcitabine in advanced breast cancer. Sem Oncol 23:77–81

    CAS  Google Scholar 

  • Catimel G, Spielmann M, Dieras V et al. (1996) Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety. Semin Oncol 23 (1, Suppl 1): 24–27

    PubMed  CAS  Google Scholar 

  • Chan S, Friedrichs K, Noel D et al. (1999) Prospective randomized trial of Docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341–2354

    PubMed  CAS  Google Scholar 

  • Chang AY, Most C, Pandya KH (1982) Continuous intravenous infusion of 5-fluorouracil in the treatment of refractory breast cancer. Am J Clin Oncol 12: 453–455

    Article  Google Scholar 

  • Chevallier B, Fumoleau P, Kerbrat P et al. (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314–322

    PubMed  CAS  Google Scholar 

  • Cobleigh MA, Vogel C, Tripathy D et al. (1998) Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:376

    Google Scholar 

  • Conte PF, Michelotti A, Baldini E et al. (1996) Epirubicin plus paclitaxel, a highly active combination devoid of significant cardiotoxicity in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:118 (Abstract 138)

    Google Scholar 

  • Degardin M, Bonneterre J, Hecquet B et al. (1994) Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5:423–426

    PubMed  CAS  Google Scholar 

  • DelMastro L, Venturini M, Lionetto R et al. (1997) Randomized phase III trial evaluating the role of erythrpoietin in the prevention of chemotherapy-induced anemia. J Clin Oncol 15: 2715–2721

    CAS  Google Scholar 

  • Dieras V, Barthier S, Beuzeboc P et al. (1998) Phase II study of docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 50:262 (abstract)

    Google Scholar 

  • Dieras V, Fumoleau P, Chevallier B et al. (1994) Second EORTC-Clinical Screening group (CSG) phase II trial of taxotere (docetaxel) as first line chemotherapy (CT) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 13:78 (abstr)

    Google Scholar 

  • Dogliotti L, Gorzegno G, Bau MG et al. (1993) Vinorelbine as second line treatment in anthracycline pre-treated advanced breast cancer patients: a phase II study. Eur J Cancer 29 A (suppl 6): 430 (abstr)

    Google Scholar 

  • Dombernowsky P, Smith I, Falkson G et al. (1998) Letrozole a new aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453–461

    PubMed  CAS  Google Scholar 

  • Dowsett M, Welch H, Blackman GM, King N, Howell A, Tobias JS, Baum M (1997) A randomized, double blind, parallelgroup trial to evaluate the effect of Arimidex (Anastrozole) on the pharmacokinetics of Tamoxifen in postmenopausal breast cancer patients. Breast 6/4: 245 (Abstr 0–74)

    Google Scholar 

  • Focan C, Andrien JM, Closon MTh et al. (1993) Dose-response relationship of Epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253–1263

    PubMed  CAS  Google Scholar 

  • Fumoleau P, Chevallier B, Kerbrat P et al. (1993) First line chemotherapy with taxotere (T) in advanced breast cancer (ABC): A phase II study of the EORTC clinical screening group (CSG). Proc Am Soc Clin Oncol 12:56 (abstr)

    Google Scholar 

  • Gamucci T, Piccart M, Bruning P et al. (1998) Single agent taxol versus doxorubicine as first-line chemotherapy in advanced breast cancer. Final results of an EORTC randomized study with crossover. Proc Am Soc Clin Oncol 17:428 (abstract)

    Google Scholar 

  • Gasparini G, Caffo O, Barni S et al. (1994) Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12:2094–2101

    PubMed  CAS  Google Scholar 

  • Gelber RD and Goldhirsch A for the Ludwig Breast Cancer Study Group (1986) A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol 4:1772–1779

    PubMed  CAS  Google Scholar 

  • Gianni L, Munzone E, Capri G et al. (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose- and sequence-finding study. J Clin Oncol 13: 2688–2699

    PubMed  CAS  Google Scholar 

  • Glaspy J, Bukowski R, Steinberg D et al. (1997) Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 15:1218–1234

    PubMed  CAS  Google Scholar 

  • Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–2205

    PubMed  CAS  Google Scholar 

  • Hansen R, Quebbeman E, Beatty P (1987) Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast. Cancer Res Treat 10:145–149

    Article  CAS  Google Scholar 

  • Holmes FA (1996) Update: The M.D. Anderson Cancer Center Experience with paclitaxel in the management of breast carcinoma. Semin Oncol 22 (Suppl 8): 9–15

    Google Scholar 

  • Hoogstraten B, Fletcher WS, Gad EL et al. (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer: A Southwest Oncology Group study. Cancer Res 42:4788–4791

    PubMed  CAS  Google Scholar 

  • Hortobagyi GN, Porter L, Blayney D et al. (1996) Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving chemotherapy (CT), by monthly pamidronate sodium (PAM) (Aredia®) infusion. Proc Am Soc Clin Oncol 15:99 (abstract)

    Google Scholar 

  • Huan S, Pazdur R, Singhakowinta A (1989) Low dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma. Cancer 63:419–422

    Article  PubMed  CAS  Google Scholar 

  • Hudis CA, Scidman AD, Crown JPA et al. (1996) Phase II and pharmacological study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14: 58–65

    PubMed  CAS  Google Scholar 

  • Ingle JN, Krook JE, Green SJ et al. (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 876–882

    Google Scholar 

  • Jabboury K, Holmes FA, Hortobagyi G (1989) 5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793–797

    Article  PubMed  CAS  Google Scholar 

  • Jackson IM, Litherland S, Wakeling AE (1991) Tamoxifen and other antiestrogens. In: Powles TJ, Smith IE (eds) Medical management of breast cancer. London: Martin Dunitz: 51–61

    Google Scholar 

  • Jonat W, Howell A, Blomqvist C et al. on behalf of the ARIMIDEX Study Group (1996) A randomised trial comparing two doses of the new selective aromatase inhibitor Anastrozole (Arimidex) with Megestrol Acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32 A: 404–412

    Article  Google Scholar 

  • Jones S, Winer L, Vogel C et al. (1994) A multicenter, randomized trial of IV Nabelbine vs IV Alkeran in patients with anthracycline-refractory advanced breast cancer (ABC). Proc Am Soc Clin Oncol 13: 216 (abstr)

    Google Scholar 

  • Kaufmann M, Bajetta E, Dirix LY et al. (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 18 (7): 1399–1411

    PubMed  CAS  Google Scholar 

  • Kaufmann M, Jonat W, Kleeberg U et al. (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7:1113–1119

    PubMed  CAS  Google Scholar 

  • Kaufmann M, Jonat W, Schachner-Wunschmann E, Bastert G, Maass H (1991) The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer — a 5 year experience and further endocrine therapies. Cooperative German Zoladex Study Group. Onkologie 14: 22–30

    Article  PubMed  CAS  Google Scholar 

  • Klijn JGM, Blarney RW, Boccardo F et al. (1998) On behalf of CHAT: a new standard treatment for advanced premenopausal breast cancer: a meta-analysis of the combined hormonal agent trialists group (CHAT). Europ J Cancer 34 (Suppl. 5): 405–410

    Google Scholar 

  • Lalisang R, Wils J, Nortier J et al. (1996) Dose intensification of epirubicin and paclitaxel with G-CSF support in metastatic breast cancer. Proc ASCO 15:99 (abstract 62)

    Google Scholar 

  • Lipton A, Leff R, Gluck S et al. (1996) Reduction of skeletal related complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly Pamidronate sodium (Aredia)®) infusion. Proc Am Soc Clin Oncol 15:152 (abstract)

    Google Scholar 

  • Littlewood TJ, Rapaport B, Bajetta E, Nortier J (2000): Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy. Proc Am Soc Clin Oncol 19, 2381 (abstract)

    Google Scholar 

  • Lokich JL, Anderson N (1993) Infusional chemotherapy for breast cancer. The Cancer Center of Boston. J Inf Chemother 3:9–14

    Google Scholar 

  • Lotz JP, Curé H, Janvier M et al. (1999) High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE 04. Proc Am Soc Clin Oncol 18:161 (abstract)

    Google Scholar 

  • Lück H J, Thomssen C, duBois A et al. (1996) Phase II study of paclitaxel and 4-epi-doxorubicin (epirubicin) as first-line therapy in patients with metastatic breast cancer. Proc ASCO 15:120 (Abstract 147)

    Google Scholar 

  • Lück HJ, Thomssen C, Untch M et al. (2000) Multicentric phase III study in first line treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs. Epirubicin/Cyclophosphamid (EC). A study of the AGO breast cancer group. Proc Am Soc Clin Oncol 19: 280 (abstract)

    Google Scholar 

  • Marty M, Extra JM, Dieras V et al. (1992) A review of the antitumor activity of vinorelbine in breast cancer. Drugs 44 (Suppl. 4): 29–35

    Article  PubMed  CAS  Google Scholar 

  • Marty M (2001) Liposomal doxorubicin (Myocet™) and conventional anthracyclines: a comparison. The Breast (Suppl 2): 28–33

    Article  Google Scholar 

  • McCormack PM, Martini N (1979) The changing role of surgery for pulmonary metastases. Ann Thorac Surg 41: 833

    Google Scholar 

  • Miller WR (1996) Aromatase inhibitors. Endocr Rel Cancer 3/1: 65–79

    Article  CAS  Google Scholar 

  • Moiseyenko V, O’Reilly SM, Talbot DC et al. (1998) A randomized phase II study of Xeloda (Capecitabine) vs. Paclitaxel in breast cancer patients failing previous anthracycline therapy. Ann Oncol 9 (Suppl 4): 620 (abstract)

    Google Scholar 

  • Mountain CF, McMurtrey MJ, Hermes KE (1984) Surgery for pulmonary metastases: a 20 year experience. Ann Thorac Surg 38:323

    Article  PubMed  CAS  Google Scholar 

  • Mouridsen H, Gershanovich M, Sun Y et al. (2001) Superior Efficacy of Letrozole Versus Tamoxifen as First Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer group. Journal of Clinical Oncology 19 (10): 2596–2606

    PubMed  CAS  Google Scholar 

  • Nabholtz JM, Buzdar A, Pollak M et al. (2000) Anastrolzole Is Superior to Tamoxifen as First Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial. Journal of Clinical Oncology 18 (22): 3758–3767

    PubMed  CAS  Google Scholar 

  • Nabholtz JM, Falkson G, Campos D et al. (1999) A phase III trial comparing Doxorubicin (D) and Docetaxel (T) (AT) to Doxorubicin and Cyclophosphamide (AC) as first line chemotherapy for MBC. Proc Am Soc Clin Oncol 18:485 (abstract)

    Google Scholar 

  • Nabholtz J-M, Gelmon K, Bontenbal M et al. (1996) Multicenter, randomized comparative study of two doses of Paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858–1867

    PubMed  CAS  Google Scholar 

  • Nabholtz J-M, Senn HJ, Bezwoda WR et al. (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413–1424

    PubMed  CAS  Google Scholar 

  • Norton L, Slamon D, Leyland-Jones B et al. (1999) Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Her-ceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18: 483 (abstract)

    Google Scholar 

  • Pollow K, Kreienberg R, Juchem M, Hoffmann G (1993) Hochdosierte Medroxyprogesteronacetat (MPA)-Therapie beim fortgeschrittenen Mammakarzinom unter besonderer Berücksichtigung der MPA-Serumspiegel. Tumordiagn Ther 14:49–55

    Google Scholar 

  • Possinger K, Wagner H, Wilmanns W (1991) Chemotherapie des fortgeschrittenen Mammakarzinoms. Krankenhausarzt 64:101–109

    Google Scholar 

  • Possinger K, Wilmanns W (1993) Palliative Therapieführung zur Hemmung der Tumorprogression bei Patientinnen mit metastasierten Mammakarzinomen. Internist 34:340–350

    PubMed  CAS  Google Scholar 

  • Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN (1997) Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemootherapy in patients with metastatic breast cancer. J Clin. Oncol. 15:3171–3177

    PubMed  CAS  Google Scholar 

  • Ranson M, Carmichael J, O’Byrne K et al. (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 15:3185–3191

    PubMed  CAS  Google Scholar 

  • Ravdin PM, Burris III HA, Cook G et al. (1995) Phase II trial of Docetaxel in advanced anthracycline-resistant or anthrace-nedione-resistant breast cancer. J Clin Oncol 13: 2879–2885

    PubMed  CAS  Google Scholar 

  • Reichman BS, Scidman AD, Crown JPA et al. (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943–1951

    PubMed  CAS  Google Scholar 

  • Rischin D, Millward MJ, Webster LK et al. (1996) Phase I study of paclitaxel and epirubicin in advanced cancer. Proc ASCO 15:480 (Abstract 1525)

    Google Scholar 

  • Sauer H (1996) Anwendung von Zytostatika. In: Tumorzentrum München (Hrsg) Empfehlungen zur Diagnostik, Therapie und Nachsorge — Mammakarzinome

    Google Scholar 

  • Schmid P and Possinger K (2001) Liposomal anthracyclines for improved cardiac tolerability. The Breast (Suppl 2): 22–27

    Google Scholar 

  • Seidman AD, Hudis CA, Albanel J et al. (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16: 3353–3361

    PubMed  CAS  Google Scholar 

  • Seidman AD, Hudis C, Crown JPA et al. (1993) Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 12: 63 (abstr)

    Google Scholar 

  • Seidman AD, Reichman BS, Crown JPA et al. (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152–1159

    PubMed  CAS  Google Scholar 

  • Sjöstrom J, Blomqvist C, Mouridsen H et al. (1999) Docetaxel compared with sequential methotrexate and 5-Fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194–1201

    Article  PubMed  Google Scholar 

  • Slamon DJ, Clark GM, Wong SG et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235:177–182

    Article  PubMed  CAS  Google Scholar 

  • Sparano JA, Ju P, Schadfer PL et al. (1998) Phase II trial of doxorubicin and docetaxel plus granulocyte-colony stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Trial (E1196). Breast Cancer Res Treat 50:27 (abstract)

    Article  Google Scholar 

  • Spielman M, Dorval T, Turpin F et al. (1994) Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 12:1764–1770

    Google Scholar 

  • Spielmann M, Llombart A, Zelek L et al. (1999) Docetaxel-cis-platin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 10: 1457–1460

    Article  PubMed  CAS  Google Scholar 

  • Stadtmauer EA, O’Neill A, Goldstein LJ et al. (1999) Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (PBT-i). Proc Am Soc Clin Oncol 18:1 (abstract)

    Google Scholar 

  • Staren ED, Salerno C, Rongione A, Witt RT, Faber P (1992) Pulmonary resection for metastatic breast cancer. Arch Surg 127:1282

    Article  PubMed  CAS  Google Scholar 

  • Tannock IF, Boyd NF, DeBoer G et al. (1988) A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377–1387

    PubMed  CAS  Google Scholar 

  • Taylor CW, Green S, Dalton WS et al. (Study Group) (1998) Multicenter randomized clinical trial of Goserelin versus surgical ovariectomy in premenopausal patients with receptor positive metastatic breast cancer: Intergroup Study. J Clin Oncol 16:994–999

    PubMed  CAS  Google Scholar 

  • ten Bokkel Huinink W, Prove AM, Piccart M et al. (1994) A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5:527–532

    Google Scholar 

  • Theodoulou M, Campos S, Welles L et al. (2001) Safety and efficiacy of TLC D-99 (Myocet®) and Trastuzumab in patients with advanced breast cancer. European Journal of Cancer 37 (Suppl. 6), abstr # 712

    Google Scholar 

  • Trudeau ME, Eisenhauer E, Lofters W et al. (1993) Phase II study of taxotere as first line chemotherapy for metastatic breast cancer (MBC). A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study. Proc Am Soc Clin Oncol 12: 64 (abstr)

    Google Scholar 

  • Valero V, Holmes FA, Walters RS et al. (1995) Phase II trial of Docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879–2885

    Google Scholar 

  • Valero V, Ravdin PM, Walters R et al. (1994) Taxotere® (docetaxel) in the treatment of anthracycline/anthracenedione-refractory metastatic breast cancer (ARMBC): combined results of 2 US phase II studies. 19th Meeting of the European Society of Medical Oncology (ESMO), Lisbon

    Google Scholar 

Download references

Authors
  1. V. Möbus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsfrauenklinik, Universität Ulm, Prittwitzstraße 43, D-89075, Ulm, Deutschland

    Rolf Kreienberg  & Tanja Volm  & 

  2. Städt. Kliniken Frankfurt-Höchst Akademisches Lehrkrankenhaus, Universität Frankfurt, Frauenklinik, Gotenstraße 6-8, D-65929, Frankfurt, Deutschland

    Volker Möbus

  3. Untere Kippstraße 21, D-69198, Schriesheim, Deutschland

    Dieter Alt

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Möbus, V., Kreienberg, R. (2002). Systemische Therapie des metastasierten Mammakarzinoms. In: Kreienberg, R., Volm, T., Möbus, V., Alt, D. (eds) Management des MAMMAKARZINOMS. Onkologie Aktuell . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-08460-1_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-08460-1_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-08461-8

  • Online ISBN: 978-3-662-08460-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation